TITLE

THE RAIDER'S RADAR

AUTHOR(S)
Bertoni, Steven
PUB. DATE
March 2011
SOURCE
Forbes Asia;Mar2011 Special Issue Billionaires, Vol. 7 Issue 4, p72
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents work profile of American corporate raider and financier Carl Icahn. Reportedly, Icahn has made a fortune of 12.5 billion dollars though several acquisitions. It describes the takeover of Genzyme Corp. by Sanofi-Aventis SA, mediated by Icahn. Icahn says, he is focusing on mergers of biotechnology companies because often these companies have overinvested but lack funds to complete their projects.
ACCESSION #
59788278

 

Related Articles

  • Genzyme Aces in Hand May Ward Off Pharma Culture War. Jungbauer, Becky // BioWorld Insight;2/28/2011, Vol. 19 Issue 9, p2 

    The article focuses on the acquisition of Genzyme Corp. by Sanofi-Aventis SA. It says that Sanofi-Aventis will have access to Genzyme's drugs for rare diseases such as cerezyme for Gaucher's disease and Fabrazyme for Fabry disease. Analyst Karen Anderson of Morningstar Inc. states that Sanofi...

  • Biotech M&A Activity on the Rise.  // Biomedical Market Newsletter;3/21/2011, p513 

    The article focuses on the rise of merger and acquisition (M&A) activities in the biotechnology industry. It states that although there has been a decrease in the number of M&A deals in the biotechnology industry for 2010, the average price per deal increased in which buyers are becoming...

  • Sanofi-Aventis: linked to biotech acquisitions.  // PharmaWatch: Biotechnology;Jan2007, Vol. 6 Issue 1, p19 

    The article reports on the attempted acquisition of U.S.-based biotech firm ImClone Systems Inc. by one of the Big Pharma players. According to the author, Sanofi-Aventis SA was rumored to have unsuccessful bid with ImClone. The issue occurred when the company's third largest shareholder Carl...

  • Sanofi-Aventis: linked to biotech acquisitions.  // PharmaWatch: Monthly Review;Nov2006, Vol. 5 Issue 11, p45 

    The article reports on the unsuccessful attempt by France-based drug company Sanofi-Aventis to acquire U.S. biotech firm ImClone Systems Inc. earlier in 2006. The attempted acquisition of ImClone Systems came to light when its third largest shareholder Carl Icahn publicly refused the bid...

  • Gold Diggers. Marino, Jonathan // Mergers & Acquisitions: The Dealermaker's Journal;Jan2011, Vol. 46 Issue 1, p12 

    The article offers information on the activist investors in the merger and acquisition (M&A) market. As stated, activist investors are increasing their activities with a focus on increasing corporate profits. Activist investor, Carl Icahn, caused Motorola Inc.'s split, separating its consumer...

  • Raiders Reborn. Creswell, Julie; Borden, Mark // Fortune;7/10/2000, Vol. 142 Issue 2, p36 

    Discusses a resurgence of the corporate raider in the United States as of July 2000, after becoming nearly extinct in the 1990's. Examples of raiders who are making a comeback, including Carl Icahn who made a bid for Nabisco in the spring of 2000; Number of deals announced by leveraged-buyout...

  • Icahn's Play for GM Puts 'Raider' in the Driver's Seat. Rynecki, David // Fortune;9/18/2000, Vol. 142 Issue 6, p46 

    Focuses on Carl Icahn, who refers to himself as a corporate 'activist', rather than a corporate raider. Speculation on why he has accumulated a major position in General Motors (GM) company, which lost $20 billion in market capital in three months; Opinion of analysts that he wants to pressure...

  • Famed Wall Street raider Icahn seeks bigger stake in Motorola. Taylor, Colleen // Electronic News;3/5/2007, Vol. 53 Issue 10, p36 

    The article reports that Wall Street corporate raider Carl Icahn has filed to acquire as much as $2 billion in additional shares of communication giant Motorola's common stock. Motorola has received notice that Icahn and Icahn Partners LP are each filing to acquire from $119.7 million to $500...

  • Is Icahn set to be King Lear? Snavely, Brent // Crain's Detroit Business;2/12/2007, Vol. 23 Issue 7, p1 

    The article focuses on a deal involving corporate raider Carl Icahn and Southfield-based Lear Corp. Icahn offered $5.3 billion in cash and stock to acquire Lear which the company accepted. After evaluating Icahn's buyout offer last week, Lear's board decided the company would benefit from the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics